Home Your basket
• Role of positron emission...
   Price 15.00 €
• Cephalic vein access for ...
   Price 10.50 €
• Bilateral cleft lip and c...
   Price 14.00 €
• Endoscopic-assisted retro...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• A survey of current wound...
   Price 5.50 €
• Polypose nasosinusienne a...
   Price 15.00 €
• Quality of life before an...
   Price 10.50 €
• Assumptions in surgical t...
   Price 8.50 €
• The pedicle superficial t...
   Price 10.50 €
• Supra and infra hyoid mid...
   Price 10.50 €
• Cellular, extracellular a...
   Price 10.50 €
• The expanding domain of i...
   Price 10.50 €
• Epistaxis and hospitalisa...
   Price 10.50 €
• Diagnostic value of vibra...
   Price 8.50 €
• Acoustic neuroma surgery....
   Price 10.50 €
• Hearing disorders at the ...
   Price 12.50 €
• Migraine, neurone and ves...
   Price 5.50 €
• Personal experience about...
   Price 10.50 €
• PET/CT in the management ...
   Price 10.50 €
• Cervical surgical emphyse...
   Price 5.50 €
• When to suspect a perilym...
   Price 10.50 €
• Mucus physiopathology, up...
   Price 12.50 €
• The jugulotympanic paraga...
   Price 10.50 €
• Evaluation and treatment ...
   Price 8.50 €
• Endoscopic endonasal surg...
   Price 8.50 €
• Notes on voice and speech...
   Price 8.50 €
• Augmentation of the abdom...
   Price 10.50 €
• Diagnosis and treatment o...
   Price 8.50 €
• Advantages of combined th...
   Price 10.50 €
• Antro choanal polyp in ch...
   Price 10.00 €
• Diagnosis and treatment o...
   Price 10.50 €
• Surgery for hyperthyroidi...
   Price 5.50 €
• Aging and life quality: A...
   Price 12.50 €
• Cervico facial lymphangio...
   Price 10.50 €
• The tensegrity concept ap...
   Price 10.50 €
• The subjective visual ver...
   Price 10.50 €
• A case of nasal foreign b...
   Price 8.50 €
• Balloon catheter dilatati...
   Price 10.50 €

Total Order 388.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2003 o

SALIVARY GLANDS

Adenoid cystic carcinoma of the head and neck: A review of 30 cases


Authors : F. Raux-Rakotomalala, Th. Houliat, J. Martel, D. Stoll, J. P. Bébéar, V. Darrouzet (Bordeaux)

Ref. : Rev Laryngol Otol Rhinol. 2003;124,4:235-241.

Article published in french
Downloadable PDF document french



Summary : Objectives: To evaluate treatment results and identify pronostics factors which determine local and regional treatment failure and crude survival in adenoid cystic tumours (ACT) in the head and neck. Methods: A retrospective study (1984 to 2001) of 30 cases of adenoid cystic tumour. The mean age was 56.9 years, with a sex ratio female to male of 2:1. Tumours of all sites were encountered, most (26.7%) being in the nose and sinuses and major salivary glands (26.6%). Tumours at the T4 stage were found in 14 cases, mainly situated in the nose and sinuses (50%). No patient had cervical lymphadenopathy, while two patients (6.7%) had bony metastases at the time of diagnosis. Two patients (6.7%) were treated by surgery alone, for T1 and T2 tumours; four patients (13%) had radiotherapy alone, and 24 patients (80%) had surgery with post-operative radiotherapy with a mean dose of 60.3 Grays (56-65 Grays). Results: local recurrence occurred in 30.8% (nine cases) after a mean interval of 43 months (1 to 10 years). Treatment of these recurrences was by revision surgery in six cases, leading to local control in one case, but in a patient with pulmonary metastases. No cases of lymph node recurrence were observed. 30% of patients developed metastases; these were pulmonary in 44% and bony in 33.3%. Mean follow-up was five years. Crude survival at 3 years was 91%, at 5 years 86%, and at 10 years 50%. The percentage tumour-free survival was 70% at 3 years, and 57% at 5 Years. 22 patients (73.3%) are still alive, 17 of them recurrence-free. Analysis of the prognostic factors has shown tumour to be more aggressive in the nose and sinuses when they presented at an advanced stage (T4); recurrence was more common when excision was incomplete, or if there was peri-neural spread. Tumours of "massive" histological type carried a poorer prognosis than those of cribrigorm type (60% death compared with 10%). The development of metastases is independent of local recurrence. Metastases to bone appear to be more rapidly aggressive than pulmonary metastases, which may remain asymptomatic for some time. Conclusion: Combined radiotherapy and surgery have allowed improved local control of ACT, but the therapeutic challenge remains the multiply recurrent ACT, or those with symptomatic metastases, and this despite new research techniques (neutral therapy, immuno-histochemistry, molecular biology). ACT are rare tumours, whose prognosis remains poor.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE